DiaMedica Therapeutics, Inc.
DMAC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 5.56%, free cash flow fell 6.75% and total debt fell 90.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow DMAC
DiaMedica Therapeutics, Inc. (DMAC) Altman Z-score
DiaMedica Therapeutics, Inc.'s Altman Z-score for fiscal 2018 is 6.68, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2018 | 6.68 | — |
How fiscal 2018’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.91 | — | 1.09 | |
| Retained earnings / total assets | (2.51) | — | −3.51 | |
| EBIT / total assets | (0.37) | — | −1.22 | |
| Market value of equity / total liabilities | 17.15 | — | 10.29 | |
| Sales / total assets | 0.03 | — | 0.03 | |
| Altman Z-score | Safe zone | 6.68 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 8.92 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | 10.3× |
| DMAC DiaMedica Therapeutics, Inc. | 6.7× |
| PRTCY PureTech Health PLC Sponsored ADR compare | 0.8× |
| OVID Ovid Therapeutics compare | 0.2× |
| PRTA Prothena Corporation plc compare | −0.2× |
| PROK ProKidney Corp. compare | −5.9× |
| INDP Indaptus Therapeutics, Inc. compare | — |
| MPLT MapLight Therapeutics, Inc. compare | — |
| EPRX Eupraxia Pharmaceuticals Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets